Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 15,000 shares at $130.40 ($1.9M) on 2012-07-26, disclosed to the SEC on 2012-07-27.
Scheduled sale ($1.9M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $126.76 | 1,987 | $252K | 13.1% |
| 2 | $126.76 | 5,994 | $760K | 39.4% |
| 3 | $130.40 | 4,519 | $589K | 30.6% |
| 4 | $131.07 | 2,500 | $328K | 17.0% |
| Total | $128.57 avg | 15,000 | $1.9M | 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |